It has been estimated that 1 out of every 8 women in the United States will develop invasive breast cancer during her lifetime. Although a diagnostic test exists to identify mutations on the BRCA1 and BRCA2 human genes, two genes associated with breast and ovarian cancer, many women are not afforded the opportunity to have testing done because Myriad Genetics holds exclusive rights over these genes. Continue Reading
The WIPO General Assembly meets from Monday, 26 September 2011 to Wednesday, 5 October 2011 and will take place at the International Conference Center Geneva (CICG), 17 rue de Varembé, 1211, Geneva.
The tentative schedule for 49th session of the WIPO General Assembly can be found here: http://www.wipo.int/edocs/mdocs/govbody/en/a_49/a_49_1_prov_2.pdf.
On 12 July 2011, the Medicines Patent Pool (MPP) and Gilead announced an agreement for Gilead to license patents for tenofovir (TDF), emtricitabine (FTC), elvitegravir (EVG), cobisistat (COBI) and a four drug combination of these drugs. KEI’s initial comments on the agreement are available here. Continue Reading
After ten years of deliberations, the 19th session (18-22 July 2011) of the WIPO Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore (IGC/GRTKF) submitted a Decision for approval to the WIPO General Assembly (26 September-5 October 2011) that could pave the way for the General Assembly in 2012 to convene a Diplomatic Conference on an international legal instrument(s) for the protection of genetic resources, traditional knowledge and traditional cultural expressions (TCEs).
L’OMPI sur la voie d’un instrument international pour la protection des ressources génétiques, des savoirs traditionnels et du folklore.
Eugenia Olliaro (KEI)
The 19th session of the WIPO Intergovernmental Committee on Intellectual Property and Genetic Resources, Traditional Knowledge and Folklore is meeting this week in Geneva (18-22 July 2011) to make a a decision on a possible international legal instrument (or instruments) to protect genetic resources, traditional knowledge and folklore. At the discussions of future work on 19 July 2011, the United States (Albert Tramposch, USPTO) asked the WIPO Legal Counsel (Edward Kwakwa) the following question.
From 27 June to 30 June 2011, representatives from the like minded group of countries including Algeria, Angola, Bangladesh, Colombia, Egypt, India, Indonesia, Malaysia, Myanmar, Namibia, Pakistan, Peru, South Africa, Tanzania, Thailand, and Zimbabwe met in Bali, Indonesia to discuss the protection of genetic resources, traditional knowledge and folklore. This group submitted a joint recommendation to the WIPO secretariat (WIPO/GRTKF/IC/19/8) requesting the following:
USPTO is currently considering a pilot program to grant priority review vouchers as an incentive mechanism for technologies or licensing that responds to humanitarian needs. KEI, MSF, Oxfam and PC previously submitted comments on November 19, 2010 and provided additional comments on March 4, 2011 with UAEM.
On 8 July 2011, the WHO Consultative Expert Working Group on R&D Financing and Coordination (CEWG) held an open session to brief the public on their preliminary assessments and recommendations.
To access the slide presentation presented by the Chair (John Arne Røttingen, Norway) and Vice-Chair (Claudia Inês Chamas, Brazil), please click on the following link: http://www.who.int/phi/news/Open_Session_July_v3.pdf
KEI comment on the Medicines Patent Pool license with Gilead
July 12, 2011
FYI: James Love (Tuesday: +44.785.543.6510, email@example.com). Thiru Balasubramaniam (firstname.lastname@example.org) or Krista Cox (email@example.com, +1.202.332.2670).